Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT06202755

Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke

Led by Kafrelsheikh University · Updated on 2024-08-20

580

Participants Needed

1

Research Sites

67 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

CONDITIONS

Official Title

Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 75 years
  • First-ever acute large-vessel ischemic stroke
  • Received antiplatelet treatment within 24 hours of stroke onset
  • Both genders included
  • Patients with previous transient ischemic attacks (TIA) allowed
  • Not eligible for rt-PA treatment
Not Eligible

You will not qualify if you...

  • Not followed up for 90 days after enrollment
  • NIHSS score ≤ 3 or ≥ 25 or rapidly resolving symptoms before imaging
  • History of persistent or recurrent CNS diseases (e.g., epilepsy, meningioma, multiple sclerosis, head trauma with residual deficit)
  • Clinical seizures at stroke onset
  • Major organ failure, active malignancies, or acute myocardial infarction within previous 6 weeks
  • Use of warfarin, regular ticagrelor during week before admission, or chemotherapy within previous year
  • Active peptic ulcers, recent gastrointestinal surgery, bleeding history within last year
  • Major surgery within last 3 months
  • Known allergy to study drugs
  • INR > 1.4 or PT > 18
  • Blood glucose < 50 or > 400 mg/dL
  • Blood pressure < 90/60 or > 185/110 mmHg on admission
  • Platelets < 100,000
  • Pregnant or lactating patients
  • Stroke due to venous thrombosis or following cardiac arrest or severe hypotension

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Kafr Elsheikh University Hospital

Kafr ash Shaykh, Egypt, 33511

Actively Recruiting

Loading map...

Research Team

M

mohamed G Zeinhom, MD

CONTACT

S

sherihan R. ahmed, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here